The U.S. Food and Drug Administration has approved the nation's first messenger RNA-based seasonal influenza vaccine for adults aged 50 and older. The vaccine, developed by Moderna and to be marketed as mFlusiva, received clearance on Wednesday, August 5, 2026, following a regulatory path that included a brief rejectio...